The Middle EAST Complement 3 Glomerulopathy Treatment Market was valued at USD 0.45 billion in 2024 and is projected to reach USD 1.20 billion by 2034, registering a CAGR of 10.0%. This growth trajectory is underpinned by the rising incidence of complement-mediated diseases, increasing awareness about early diagnosis and treatment options, and advancements in therapeutic technologies. The...